EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Commentary on “Asymmetric Dimethylarginine as a Potential Biomarker for Cardiovascular Risk Assessment in Long-Standing Type 1 Diabetes Mellitus”

Can Lin

Galician Medical Journal · 24.04.2026 · 33 (2)

DOI: 10.21802/e-gmj2026-a08 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Galician Medical Journal, online erschienen am 24.04.2026. Verfasst von Can Lin. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asymmetric dimethylarginine (ADMA) has been discussed as a potential biomarker of cardiovascular risk, but its interpretation in type 1 diabetes mellitus (T1DM) remains context-dependent. In commenting on the recent study by Chausheva et al., we suggest that the findings should be interpreted cautiously rather than viewed as definitively excluding clinical relevance. In addition to glycemic status, kidney function, and biological sex, ADMA concentrations may also be influenced by smoking exposure, physical inactivity, inflammatory status, and medication use. These factors may complicate its interpretation as a universal cardiovascular risk marker in heterogeneous T1DM populations. ADMA may therefore be more appropriately considered in selected phenotypes or as part of a broader multivariable framework rather than as a standalone indicator.

Zitieren

APA

Lin, C. (2026). Commentary on “Asymmetric Dimethylarginine as a Potential Biomarker for Cardiovascular Risk Assessment in Long-Standing Type 1 Diabetes Mellitus”. Galician Medical Journal, 33(2). https://doi.org/10.21802/e-gmj2026-a08

Vancouver

Lin C. Commentary on “Asymmetric Dimethylarginine as a Potential Biomarker for Cardiovascular Risk Assessment in Long-Standing Type 1 Diabetes Mellitus”. Galician Medical Journal. 2026;33(2). doi:10.21802/e-gmj2026-a08

BibTeX
@article{Lin2026,
  author = {Lin, Can},
  title = {Commentary on “Asymmetric Dimethylarginine as a Potential Biomarker for Cardiovascular Risk Assessment in Long-Standing Type 1 Diabetes Mellitus”},
  journal = {Galician Medical Journal},
  year = {2026},
  volume = {33},
  number = {2},
  doi = {10.21802/e-gmj2026-a08}
}
Kostenlos starten →